Nat Cancer: Neoadjuvant therapy drugs cabozantinib and nivolumab in the treatment of locally advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) more than 90% of all primary liver cancer, the disease usually develops from chronic liver disease, including alcoholic liver disease, chronic viral hepatitis (B or C), and non-alcoholic fatty liver disease
.

Hepatocellular carcinoma (HCC) more than 90% of all primary liver cancer, the disease usually develops from chronic liver disease, including alcoholic liver disease, chronic viral hepatitis (B or C), and non-alcoholic fatty liver disease
.

Hepatocellular carcinoma (HCC) more than 90% of all primary liver cancer, the disease usually develops from chronic liver disease, including alcoholic liver disease, chronic viral hepatitis (B or C), and non-alcoholic fatty liver disease

HCC is the fourth leading cause of cancer-related deaths, and its mortality rate is increasing year by year in the United States and many parts of the world
.

Potentially curative hepatectomy is the best treatment for HCC, but most patients are not suitable for resection, and most HCC patients undergoing resection will eventually relapse

Since negative margins are usually observed during surgical resection, it is believed that the recurrence of HCC is usually caused by micrometastases that persist after resection
.

Therefore, perioperative treatment strategies that can reduce the burden of micrometastasis may improve the prognosis of patients

Previous studies have shown that for certain cancers, neoadjuvant treatment strategies can reduce the size of tumors, allowing patients with locally advanced or unresectable cancers to obtain secondary resectability
.

However, the neoadjuvant systemic treatment strategy for HCC patients has been limited by the lack of effective systemic drug treatments, and currently no relevant systemic therapy is approved for the neoadjuvant treatment of HCC

The clinical response of the neoadjuvant drugs cabozantinib and nivolumab

The clinical response of the neoadjuvant drugs cabozantinib and nivolumab

The study is a single-arm phase 1b clinical trial.

In this study, researchers aim to evaluate the feasibility of the neoadjuvant drugs cabozantinib and nivolumab in HCC patients, including Patients outside the traditional resection criteria

The researchers aimed to evaluate the feasibility of the neoadjuvant drugs cabozantinib and nivolumab in HCC patients, including those outside the traditional resection criteria

Cabozantinib can enhance systemic and local anti-tumor T cell responses

Cabozantinib can enhance systemic and local anti-tumor T cell responses

All in all, the results of the study reveal that cabozantinib and nivolumab, as a reasonable combination of treatments, can be used to test the effectiveness of neoadjuvant therapy for resectable or locally advanced HCC
.

Cabozantinib and nivolumab, as a reasonable combination of treatment, can be used to test the effectiveness of neoadjuvant therapy for resectable or locally advanced HCC
.

Cabozantinib and nivolumab, as a reasonable combination of treatment, can be used to test the effectiveness of neoadjuvant therapy for resectable or locally advanced HCC

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity.

 

Leave a message here